Você está na página 1de 14

Antibiotic resistance

Antibiotic resistance
Antibiotic resistance is a form of drug resistance whereby some (or, less commonly, all) sub-populations of a microorganism, usually a bacterial species, are able to survive after exposure to one or more antibiotics; pathogens resistant to multiple antibiotics are considered multidrug resistant (MDR) or, more colloquially, superbugs. Microbes, rather than people, develop resistance to antibiotics.[]
Antibiotic resistance tests: The bacteria in the Antibiotic resistance is a serious and growing phenomenon in culture on the left are sensitive to the antibiotics contemporary medicine and has emerged as one of the pre-eminent contained in the white, paper discs. The bacteria public health concerns of the 21st century, particularly as it pertains to in the culture on the right are resistant to most of pathogenic organisms (the term is especially relevant to organisms the antibiotics. which cause disease in humans). In the simplest cases, drug-resistant organisms may have acquired resistance to first-line antibiotics, thereby necessitating the use of second-line agents. Typically, a first-line agent is selected on the basis of several factors including safety, availability and cost; a second-line agent is usually broader in spectrum, has a less favourable risk-benefit profile and is more expensive or, in dire circumstances, be locally unavailable. In the case of some MDR pathogens, resistance to second and even third-line antibiotics is thus sequentially acquired, a case quintessentially illustrated by Staphylococcus aureus in some nosocomial settings. Some pathogens, such as Pseudomonas aeruginosa, also possess a high level of intrinsic resistance.

It may take the form of a spontaneous or induced genetic mutation, or the acquisition of resistance genes from other bacterial species by horizontal gene transfer via conjugation, transduction, or transformation. Many antibiotic resistance genes reside on transmissible plasmids, facilitating their transfer. Exposure to an antibiotic naturally selects for the survival of the organisms with the genes for resistance. In this way, a gene for antibiotic resistance may readily spread through an ecosystem of bacteria. Antibiotic-resistance plasmids frequently contain genes conferring resistance to several different antibiotics. This is not the case for Mycobacterium tuberculosis, the bacteria that causes Tuberculosis, since evidence is lacking for whether these bacteria have plasmids.[] Also. M. tuberculosis lack the opportunity to interact with other bacteria in order to share plasmids.[][1] Genes for resistance to antibiotics, like the antibiotics themselves, are ancient.[2] However, the increasing prevalence of antibiotic-resistant bacterial infections seen in clinical practice stems from antibiotic use both within human medicine and veterinary medicine. Any use of antibiotics can increase selective pressure in a population of bacteria to allow the resistant bacteria to thrive and the susceptible bacteria to die off. As resistance towards antibiotics becomes more common, a greater need for alternative treatments arises. However, despite a push for new antibiotic therapies there has been a continued decline in the number of newly approved drugs.[3] Antibiotic resistance therefore poses a significant problem. The growing prevalence and incidence of infections due to MDR pathogens is epitomised by the increasing number of familiar acronyms used to describe the causative agent and sometimes the infection generally; of these, MRSA is probably the most well-known, but others including VISA (vancomycin-intermediate S. aureus), VRSA (vancomycin-resistant S. aureus), ESBL (Extended spectrum beta-lactamase), VRE (Vancomycin-resistant Enterococcus) and MRAB (Multidrug-resistant A. baumannii) are prominent examples. Nosocomial infections overwhelmingly dominate cases where MDR pathogens are implicated, but multidrug-resistant infections are also becoming increasingly common in the community.

Antibiotic resistance

Although there were low levels of preexisting antibiotic-resistant bacteria before the widespread use of antibiotics,[4] [5] evolutionary pressure from their use has played a role in the development of multidrug resistance varieties and the spread of resistance between bacterial species.[6] In medicine, the major problem of the emergence of resistant bacteria is due to misuse and overuse of antibiotics.[7] In some countries, antibiotics are sold over the counter without a prescription, which also leads to the creation of resistant strains. Other practices contributing towards resistance include the addition of antibiotics to livestock feed.[8][] Household use of antibacterials in soaps and other products, although not clearly contributing to resistance, is also discouraged (as not being effective at infection control).[9] Unsound practices in the pharmaceutical manufacturing industry can also contribute towards the likelihood of creating antibiotic-resistant strains.[10] The procedures and clinical practice during the period of drug treatment are frequently flawed usually no steps are taken to isolate the patient to prevent re-infection or infection by a new pathogen, negating the goal of complete destruction by the end of the course.[11] (see Healthcare-associated infections and Infection control) Certain antibiotic classes are highly associated with colonisation with "superbugs" compared to other antibiotic classes. A superbug, also called multiresistant, is a bacterium that carries several resistance genes. [12] The risk for colonisation increases if there is a lack of sensitivity (resistance) of the superbugs to the antibiotic used and high tissue penetration, as well as broad-spectrum activity against "good bacteria". In the case of MRSA, increased rates of MRSA infections are seen with glycopeptides, cephalosporins and especially quinolones.[13][14] In the case of colonisation with Clostridium difficile the high risk antibiotics include cephalosporins and in particular quinolones and clindamycin.[15][16] Of antibiotics used in the United States in 1997, half were used in humans and half in animals.[17]

Natural occurrence
There is evidence that naturally occurring antibiotic resistance is common.[] The genes that confer this resistance are known as the environmental resistome.[] These genes may be transferred from non-disease-causing bacteria to those that do cause disease, leading to clinically significant antibiotic resistance.[] In 1952 an experiment conducted by Joshua and Esther Lederberg showed that penicillin-resistant bacteria existed before penicillin treatment.[18] While experimenting at the University of Wisconsin-Madison, Joshua Lederberg and his graduate student Norton Zinder also demonstrated preexistent bacterial resistance to streptomycin.[19] In 1962, the presence of penicillinase was detected in dormant Bacillus licheniformis endospores, revived from dried soil on the roots of plants, preserved since 1689 in the British Museum.[20][21][22] Six strains of Clostridium, found in the bowels of William Braine and John Hartnell (members of the Franklin Expedition) showed resistance to cefoxitin and clindamycin.[23] It was suggested that penicillinase may have emerged as a defense mechanism for bacteria in their habitats, such as the case of penicillinase-rich Staphylococcus aureus, living with penicillin-producing Trichophyton, however this was deemed circumstantial.[22] Search for a penicillinase ancestor has focused on the class of proteins that must be a priori capable of specific combination with penicillin.[24] The resistance to cefoxitin and clindamycin in turn was attributed to Braine's and Hartnell's contact with microorganisms that naturally produce them or random mutation in the chromosomes of Clostridium strains.[23] Nonetheless there is evidence that heavy metals and some pollutants may select for antibiotic-resistant bacteria, generating a constant source of them in small numbers.[25]

Antibiotic resistance

In medicine
The sheer volume of antibiotics prescribed is the major factor in the increasing rates of bacterial resistance rather than non-compliance with antibiotic protocol [] A single dose of antibiotics leads to a greater risk of resistant organisms to that antibiotic in the person for up to a year.[26] Inappropriate prescribing of antibiotics has been attributed to a number of causes, including people who insist on antibiotics, physicians who simply prescribe them as they feel they do not have time to explain why they are not necessary, and physicians who do not know when to prescribe antibiotics or else are overly cautious for medical legal reasons.[27] For example, a third of people believe that antibiotics are effective for the common cold,[28] and the common cold is the most common reasons antibiotics are prescribed[29] even though antibiotics are completely useless against viruses. Antibiotic resistance has been shown to increase with duration of treatment; therefore, as long as a clinically effective lower limit is observed (that depends upon the organism and antibiotic in question), the use by the medical community of shorter courses of antibiotics is likely to decrease rates of resistance, reduce cost, and have better outcomes due to fewer complications such as C. difficile infection and diarrhea.[30][31][32][33][34][35][36][37] In some situations a short course is inferior to a long course.[38] One study found that with one antibiotic a short course was more effective, but with a different antibiotic, a longer course was more effective.[39] Advice to always complete a course of antibiotics is not based on strong evidence, and some researchers discourage the use of the prescription label Finish all this medication unless otherwise directed by prescriber. Often, antibiotics can be safely stopped 72 hours after symptoms resolve.[40] However, some infections require treatment long after symptoms are gone, and in all cases, an insufficient course of antibiotics may lead to relapse (with an infection that is now more antibiotic resistant).[41] Doctors must provide instructions to patients so they know when it is safe to stop taking a prescription since patients may feel better before the infection is eradicated. Some researchers advocate doctors' using a very short course of antibiotics, reevaluating the patient after a few days, and stopping treatment if there are no longer clinical signs of infection.[42] A large number of people do not finish a course of antibiotics primarily because they feel better (varying from 10% to 44%, depending on the country).[43] Compliance with once-daily antibiotics is better than with twice-daily antibiotics.[44] Patients taking less than the required dosage or failing to take their doses within the prescribed timing results in decreased concentration of antibiotics in the bloodstream and tissues, and, in turn, exposure of bacteria to suboptimal antibiotic concentrations increases the frequency of antibiotic resistant organisms.[45] Antibiotic-tolerant states may depend on physiological adaptations without direct connections to antibiotic target activity or to drug uptake, efflux, or inactivation. Identifying these adaptations, and targeting them to enhance the activity of existing drugs, is a promising approach to mitigate the public health crisis caused by the scarcity of new antibiotics.[citation needed] Poor hand hygiene by hospital staff has been associated with the spread of resistant organisms,[46] and an increase in hand washing compliance results in decreased rates of these organisms.[47] The improper use of antibiotics and therapeutic treatments can often be attributed to the presence of structural violence in particular regions. Socioeconomic factors such as race and poverty affect the accessibility of and adherence to drug therapy. The efficacy of treatment programs for these drug-resistant strains depends on whether or not programmatic improvements take into account the effects of structural violence.[48]

Antibiotic resistance

Role of other animals

Drugs are used in animals that are used as human food, such as cattle, pigs, chickens, fish, etc. There has been extensive use of antibiotics in animal husbandry. Many of these drugs are not considered significant drugs for use in humans, either because of their lack of efficacy or purpose in humans, (such as the use of ionopores in ruminants[49]) or because that drug has gone out of use in humans (such as the decline in use of Sulfonamide_(medicine) due to widespread allergic reactions and antibiotic resistance among human pathogens.) Historically, regulation of antibiotic use in food animals has been limited to limiting drug residues in meat, egg, and milk products, rather than concern over the development of antibiotic resistance. This mirrors the primary concerns in human medicine, where researchers and doctors were historically more concerned about effective but non-toxic doses of drugs rather than antibiotic resistance. Evidence for the transfer of so-called superbugs from animals to humans has been scant, and most evidence shows that pathogens of concern in human populations originated in humans and are maintained there, with rare cases of transference to humans. One of the pathogens most frequently cited in popular literature MRSA is largely maintained in the human population, often asyptomatically, and until recently has rarely been found in food or companion animals.[50][51] More significantly, evidence for the transference of fluoroquinolone resistant genes in Camploybacteria strains through poultry was cited as justification for severely restricting veterinary use of fluoroquinolones in food animals in the USA. (Use in companion animals is still permitted, and fluoroquinolones are the most commonly prescribed antibiotic to adult humans in the United States, despite guidelines which recommend it only be used in severe infections.) The resistant bacteria in animals due to antibiotic exposure can be transmitted to humans via three pathways, those being through the consumption of meat, from close or direct contact with animals, or through the environment.[52]/ However, complete cooking of meat inactivates bacteria, whether or not they are antibiotic-resistant. The World Health Organization concluded antibiotics as growth promoters in animal feeds should be prohibited, in the absence of risk assessments. In 1998, European Union health ministers voted to ban four antibiotics widely used to promote animal growth (despite their scientific panel's recommendations). Regulation banning the use of antibiotics in European feed, with the exception of two antibiotics in poultry feeds, became effective in 2006.[53] In Scandinavia, there is evidence that the ban has led to a lower prevalence of antimicrobial resistance in (nonhazardous) animal bacterial populations.[54] In the USA, federal agencies do not collect data on antibiotic use in animals, but animal-to-human spread of drug-resistant organisms has been demonstrated in research studies. Antibiotics are still used in U.S. animal feed, along with other ingredients that represent safety concerns.[][55] Growing U.S. consumer concern about using antibiotics in animal feed has led to a niche market of "antibiotic-free" animal products, but this small market is unlikely to change entrenched, industry-wide practices.[56] In 2001, the Union of Concerned Scientists estimated that greater than 70% of the antibiotics used in the US are given to food animals (for example, chickens, pigs and cattle), in the absence of disease.[57] Hence, the amounts given are termed "sub-therapeutic", i.e., insufficient to combat diseasebecause no demonstrable disease is present. Sub-therapeutic dosages kills some, but not all, of the bacterial organisms in the animalleaving those that are naturally antibiotic-resistant. Studies have shown, however, that the overall population levels of bacteria are essentially unchanged; only the mix of bacteria is affected.[citation needed] Thus the actual mechanism by which sub-therapeutic antibiotic feed additives serve as growth promotors is unclear. Some people have speculated that animals and fowl in feedlot environments may have sub-clinical infections, which are cured by low levels of antibiotics in feed, thereby allowing the creatures to thrive; but no convincing evidence has been advanced for this theory. As the bacterial load in an animal is essentially unchanged by use of antibiotic feed additives, the mechanism of growth promotion is overwhelmingly likely to be something other than "killing off the bad bugs." In 2000, the US Food and Drug Administration (FDA) announced their intention to revoke approval of fluoroquinolone use in poultry production because of substantial evidence linking it to the emergence of

Antibiotic resistance fluoroquinolone-resistant Campylobacter infections in humans. The final decision to ban fluoroquinolones from use in poultry production was not made until five years later because of challenges from the food animal and pharmaceutical industries.[] During 2007, two federal bills (S. 549[58] and H.R. 962[59]) aimed at phasing out "nontherapeutic" antibiotics in US food animal production. The Senate bill, introduced by Sen. Edward "Ted" Kennedy, died. The House bill, introduced by Rep. Louise Slaughter, died after being referred to Committee. In the United States In the United States, evidence of emergence of antibiotic-resistant bacterial strains due to wide use of antibiotics to promote weight gain in livestock was determined by the United States Food and Drug Administration in 1977, but nothing effective was done to prevent the practice. In March, 2012 the United States District Court for the Southern District of New York, ruling in an action brought by the Natural Resources Defense Council and others, ordered the FDA to revoke approvals for the use of antibiotics in livestock which violated FDA regulations.[] On April 11, 2012 the FDA announced a voluntary program to phase out unsupervised use of drugs as feed additives and convert approved over-the-counter uses for antibiotics to prescription use only, requiring veterinarian supervision of their use and a prescription.[][]

Environmental Impact
Antibiotics have been polluting the environment since their introduction through human waste (medication, farming), animals, and the pharmaceutical industry.[60] Along with antibiotic waste, resistant bacteria follow, thus introducing antibiotic resistant bacteria into the environment. As bacteria replicate quickly, the resistant bacteria that enter the environment replicate their resistance genes as they continue to divide. Additionally, bacteria carrying resistance genes have the ability to spread those genes to other species via horizontal gene transfer. Therefore, even if the specific antibiotic is no longer introduced into the environment, antibiotic resistance genes will persist through the bacteria that have since replicated without continual exposure.[60] A study done of the Poudre River implicated wastewater treatment plants, as well as animal feeding operations in the dispersal of antibiotic resistance genes into the environment.[61] This research was done using molecular signatures in order to determine the sources, and the location at the Poudre River was chosen due to lack of other anthropogenic influences upstream. The study indicates that monitoring of antibiotic resistance genes may be useful in determining not only the point of origin of their release, but also how these genes persist in the environment. Additionally, studying physical and chemical methods of treatment may alleviate pressure of antibiotic resistance genes in the environment, and thus their entry back into human contact.

Antibiotic resistance

Antibiotic resistance can be a result of horizontal gene transfer,[62] and also of unlinked point mutations in the pathogen genome at a rate of about 1 in 108 per chromosomal replication. The antibiotic action against the pathogen can be seen as an environmental pressure. Those bacteria with a mutation that allows them to survive live to reproduce. They then pass this trait to their offspring, which leads to the evolution of a fully resistant colony. The four main mechanisms by which microorganisms exhibit resistance to antimicrobials are: 1. Drug inactivation or modification: for example, enzymatic deactivation of penicillin G in some penicillin-resistant bacteria through the production of -lactamases 2. Alteration of target site: for example, alteration of PBPthe binding target site of penicillinsin MRSA and other penicillin-resistant bacteria 3. Alteration of metabolic pathway: for example, some sulfonamide-resistant bacteria do not require para-aminobenzoic acid (PABA), an important precursor for the synthesis of folic acid and nucleic acids in bacteria inhibited by sulfonamides, instead, like mammalian cells, they turn to using preformed folic acid. 4. Reduced drug accumulation: by decreasing drug permeability and/or increasing active efflux (pumping out) of the drugs across the cell surface[63] There are three known mechanisms of fluoroquinolone resistance. Some types of efflux pumps can act to decrease intracellular quinolone concentration.[64] In Gram-negative bacteria, plasmid-mediated resistance genes produce proteins that can bind to DNA gyrase, protecting it from the action of quinolones. Finally, mutations at key sites in DNA gyrase or topoisomerase IV can decrease their binding affinity to quinolones, decreasing the drug's effectiveness.[65] Research has shown the bacterial protein LexA may play a key role in the acquisition of bacterial mutations giving resistance to quinolones and rifampicin.[66]

Schematic representation of how antibiotic resistance evolves via natural selection. The top section represents a population of bacteria before exposure to an antibiotic. The middle section shows the population directly after exposure, the phase in which selection took place. The last section shows the distribution of resistance in a new generation of bacteria. The legend indicates the resistance levels of individuals.

Antibiotic resistance can also be introduced artificially into a alteration of the antibiotic's target site, modeled microorganism through laboratory protocols, sometimes used as a after MRSA's resistance to penicillin. Beta-lactam selectable marker to examine the mechanisms of gene transfer or to antibiotics permanently inactivate PBP enzymes, which are essential for bacterial life, by identify individuals that absorbed a piece of DNA that included the permanently binding to their active sites. MRSA, resistance gene and another gene of interest. A recent study however, expresses a PBP that does not allow the demonstrated that the extent of horizontal gene transfer among antibiotic into its active site. Staphylococcus is much greater than previously expectedand encompasses genes with functions beyond antibiotic resistance and virulence, and beyond genes residing within the mobile genetic elements.[67] For a long time it has been thought that for a microorganism to become resistant to an antibiotic, it must be in a large population. However, recent findings show that there is no necessity of large populations of bacteria for the

Diagram depicting antibiotic resistance through

Antibiotic resistance appearance of antibiotic resistance. We know now, that small populations of E.coli in an antibiotic gradient can become resistant. Any heterogeneous environment with respect to nutrient and antibiotic gradients may facilitate the development of antibiotic resistance in small bacterial populations and this is also true for the human body. Researchers hypothesize that the mechanism of resistance development is based on four SNP mutations in the genome of E.coli produced by the gradient of antibiotic. These mutations confer the bacteria emergence of antibiotic resistance. A common misconception is that a person can become resistant to certain antibiotics. It is a strain of microorganism that can become resistant, not a person's body.[68][69]

Resistant pathogens
Staphylococcus aureus
Staphylococcus aureus (colloquially known as "Staph aureus" or a "Staph infection") is one of the major resistant pathogens. Found on the mucous membranes and the human skin of around a third of the population, it is extremely adaptable to antibiotic pressure. It was one of the earlier bacteria in which penicillin resistance was foundin 1947, just four years after the drug started being mass-produced. Methicillin was then the antibiotic of choice, but has since been replaced by oxacillin due to significant kidney toxicity. Methicillin-resistant Staphylococcus aureus (MRSA) was first detected in Britain in 1961, and is now "quite common" in hospitals. MRSA was responsible for 37% of fatal cases of sepsis in the UK in 1999, up from 4% in 1991. Half of all S. aureus infections in the US are resistant to penicillin, methicillin, tetracycline and erythromycin. This left vancomycin as the only effective agent available at the time. However, strains with intermediate (4-8g/ml) levels of resistance, termed glycopeptide-intermediate Staphylococcus aureus (GISA) or vancomycin-intermediate Staphylococcus aureus (VISA), began appearing in the late 1990s. The first identified case was in Japan in 1996, and strains have since been found in hospitals in England, France and the US. The first documented strain with complete (>16g/ml) resistance to vancomycin, termed vancomycin-resistant Staphylococcus aureus (VRSA) appeared in the United States in 2002.[70] However, in 2011 a variant of vancomycin has been tested that binds to the lactate variation and also binds well to the original target, thus reinstates potent antimicrobial activity.[71] A new class of antibiotics, oxazolidinones, became available in the 1990s, and the first commercially available oxazolidinone, linezolid, is comparable to vancomycin in effectiveness against MRSA. Linezolid-resistance in S. aureus was reported in 2001.[72] Community-acquired MRSA (CA-MRSA) has now emerged as an epidemic that is responsible for rapidly progressive, fatal diseases, including necrotizing pneumonia, severe sepsis and necrotizing fasciitis.[] MRSA is the most frequently identified antimicrobial drug-resistant pathogen in US hospitals. The epidemiology of infections caused by MRSA is rapidly changing. In the past 10 yearsWikipedia:Manual of Style/Dates and numbers#Chronological items, infections caused by this organism have emerged in the community. The two MRSA clones in the United States most closely associated with community outbreaks, USA400 (MW2 strain, ST1 lineage) and USA300, often contain Panton-Valentine leukocidin (PVL) genes and, more frequently, have been associated with skin and soft tissue infections. Outbreaks of CA-MRSA infections have been reported in correctional facilities, among athletic teams, among military recruits, in newborn nurseries, and among men who have sex with men. CA-MRSA infections now appear endemic in many urban regions and cause most CA-S. aureus infections.[]

Antibiotic resistance

Streptococcus and Enterococcus

Streptococcus pyogenes (Group A Streptococcus: GAS) infections can usually be treated with many different antibiotics. Early treatment may reduce the risk of death from invasive group A streptococcal disease. However, even the best medical care does not prevent death in every case. For those with very severe illness, supportive care in an intensive care unit may be needed. For persons with necrotizing fasciitis, surgery often is needed to remove damaged tissue.[73] Strains of S. pyogenes resistant to macrolide antibiotics have emerged; however, all strains remain uniformly sensitive to penicillin.[] Resistance of Streptococcus pneumoniae to penicillin and other beta-lactams is increasing worldwide. The major mechanism of resistance involves the introduction of mutations in genes encoding penicillin-binding proteins. Selective pressure is thought to play an important role, and use of beta-lactam antibiotics has been implicated as a risk factor for infection and colonization. S. pneumoniae is responsible for pneumonia, bacteremia, otitis media, meningitis, sinusitis, peritonitis and arthritis.[] Multidrug-resistant Enterococcus faecalis and Enterococcus faecium are associated with nosocomial infections.[] Among these strains, penicillin-resistant Enterococcus was seen in 1983, vancomycin-resistant Enterococcus in 1987, and linezolid-resistant Enterococcus in the late 1990s.[citation needed]

Pseudomonas aeruginosa
Pseudomonas aeruginosa is a highly prevalent opportunistic pathogen. One of the most worrisome characteristics of P. aeruginosa is its low antibiotic susceptibility, which is attributable to a concerted action of multidrug efflux pumps with chromosomally encoded antibiotic resistance genes (for example, mexAB-oprM, mexXY, etc.) and the low permeability of the bacterial cellular envelopes.[] Pseudomonas aeruginosa has the ability to produce HAQs and it has been found that HAQs have prooxidant effects, and overexpressing modestly increased susceptibility to antibiotics. The study experimented with the Pseudomonas aeruginosa biofilms and found that a disruption of relA and spoT genes produced an inactivation of the Stringent response (SR) in cells who were with nutrient limitation which provides cells be more susceptible to antibiotics.[74]

Clostridium difficile
Clostridium difficile is a nosocomial pathogen that causes diarrheal disease in hospitals world wide.[75][] Clindamycin-resistant C. difficile was reported as the causative agent of large outbreaks of diarrheal disease in hospitals in New York, Arizona, Florida and Massachusetts between 1989 and 1992.[] Geographically dispersed outbreaks of C. difficile strains resistant to fluoroquinolone antibiotics, such as ciprofloxacin and levofloxacin, were also reported in North America in 2005.[]

Salmonella and E. coli

Escherichia coli and Salmonella come directly from contaminated food. When both bacteria are spread, serious health conditions arise. Many people are hospitalized each year after becoming infected, with some dying as a result. By 1993, E. coli resistant to multiple fluoroquinolone variants was documented.[citation needed]

Acinetobacter baumannii
On November 5, 2004, the Centers for Disease Control and Prevention (CDC) reported an increasing number of Acinetobacter baumannii bloodstream infections in patients at military medical facilities in which service members injured in the Iraq/Kuwait region during Operation Iraqi Freedom and in Afghanistan during Operation Enduring Freedom were treated. Most of these showed multidrug resistance (MRAB), with a few isolates resistant to all drugs tested.[][76]

Antibiotic resistance

Mycobacterium tuberculosis
Tuberculosis is increasing across the globe, especially in developing countries, over the past few years. TB resistant to antibiotics is called MDR TB (Multidrug Resistant TB). The rise of the HIV/AIDS epidemic has contributed to this.[] TB was considered one of the most prevalent diseases, and did not have a cure until the discovery of Streptomycin by Selman Waksman in 1943.[77] However, the bacteria soon developed resistance. Since then, drugs such as isoniazid and rifampin have been used. M. tuberculosis develops resistance to drugs by spontaneous mutations in its genomes. Resistance to one drug is common, and this is why treatment is usually done with more than one drug. Extensively Drug Resistant TB (XDR TB) is TB that is also resistant to the second line of drugs.[][78] Resistance of Mycobacterium tuberculosis to isoniazid, rifampin, and other common treatments has become an increasingly relevant clinical challenge. (For more on Drug Resistant TB, visit the Multi-drug resistant tuberculosis page.)

Rational use of antibiotics may reduce the chances of development of opportunistic infection by antibiotic-resistant bacteria due to dysbacteriosis.Our immune systems will cure minor bacterial infections on their own. If we give it the chance without relying on antibiotics to cure a small infection, we will be less likely to become immune or resistant to the antibiotic. It is also important to note that antibiotics will not cure viral infections. Taking an antibiotic unnecessarily to treat a viral infection can lead to the resistance of antibiotics[79] In one study, the use of fluoroquinolones is clearly associated with Clostridium difficile infection, which is a leading cause of nosocomial diarrhea in the United States,[] and a major cause of death, worldwide.[] Vaccines do not have the problem of resistance because a vaccine enhances the body's natural defenses, while an antibiotic operates separately from the body's normal defenses. Nevertheless, new strains may evolve that escape immunity induced by vaccines; for example an updated influenza vaccine is needed each year. While theoretically promising, antistaphylococcal vaccines have shown limited efficacy, because of immunological variation between Staphylococcus species, and the limited duration of effectiveness of the antibodies produced. Development and testing of more effective vaccines is under way. [80] The Australian Commonwealth Scientific and Industrial Research Organization (CSIRO), realizing the need for the reduction of antibiotic use, has been working on two alternatives. One alternative is to prevent diseases by adding cytokines instead of antibiotics to animal feed. [] These proteins are made in the animal body "naturally" after a disease and are not antibiotics, so they do not contribute to the antibiotic resistance problem. Furthermore, studies on using cytokines have shown they also enhance the growth of animals like the antibiotics now used, but without the drawbacks of nontherapeutic antibiotic use. Cytokines have the potential to achieve the animal growth rates traditionally sought by the use of antibiotics without the contribution of antibiotic resistance associated with the widespread nontherapeutic uses of antibiotics currently used in the food animal production industries. Additionally, CSIRO is working on vaccines for diseases. [] In the United States, several initiatives to reduce the amount of prescription antibiotics have been introduced. Health Net of California's Medi-Cal managed care plan provides physicians a quarterly report that benchmarks individual performance related to prescribing of antibiotics to treat upper respiratory infection (i.e., the common cold) in children and adolescents versus that of peers, along with a list of child and adolescent patients of that physician who may have been inappropriately prescribed antibiotics for such an infection in the past year.[81] In 2007, a family practice physician training program known as DECISION+2 reduced use of antibiotics for acute respiratory infections and allowed patients to take a more active role in decisionmaking, without having a negative impact on

Antibiotic resistance patient outcomes.[82] In 2007, Sonoma Valley Hospital instituted a telemedicine-based antimicrobial stewardship program designed to improve prescribing ofand reduce bacterial resistance toantibiotics, as required by California law.[83]


Phage therapy
Phage therapy, an approach that has been extensively researched and used as a therapeutic agent for over 60 years, especially in the Soviet Union, represents a potentially significant but currently underdeveloped approach to the treatment of bacterial disease.[84] Phage therapy was widely used in the United States until the discovery of antibiotics, in the early 1940s. Bacteriophages or "phages" are viruses that invade bacterial cells and, in the case of lytic phages, disrupt bacterial metabolism and cause the bacterium to lyse. Phage therapy is the therapeutic use of lytic bacteriophages to treat pathogenic bacterial infections.[85] [86] [87] Bacteriophage therapy is an important alternative to antibiotics in the current era of multidrug resistant pathogens. A review of studies that dealt with the therapeutic use of phages from 19661996 and few latest ongoing phage therapy projects via internet showed: phages were used topically, orally or systemically in Polish and Soviet studies. The success rate found in these studies was 8095% with few gastrointestinal or allergic side effects. British studies also demonstrated significant efficacy of phages against Escherichia coli, Acinetobacter spp., Pseudomonas spp. and Staphylococcus aureus. US studies dealt with improving the bioavailability of phage. Phage therapy may prove as an important alternative to antibiotics for treating multidrug resistant pathogens.[88] Discovery of the structure of the viral protein PlyC is allowing researchers to understand the way it kills a significant range of pathogenic bacteria.[89]

New medications
Until recently, research and development (R&D) efforts have provided new drugs in time to treat bacteria that became resistant to older antibiotics. However: "The supply of new replacement antimicrobial agents has slowed dramatically and we face the prospect of a future where we have far fewer options in the treatment of infectious disease"[90] The potential crisis at hand is the result of a marked decrease in industry R&D, and the increasing prevalence of resistant bacteria. Infectious disease physicians are alarmed by the prospect that effective antibiotics may not be available to treat seriously ill patients in the near future.[] Poor financial investment in antibiotic research has exacerbated the situation[] In research published on October 17, 2008 in Cell, a team of scientists pinpointed the place on bacteria where the antibiotic myxopyronin launches its attack, and why that attack is successful. The myxopyronin binds to and inhibits the crucial bacterial enzyme, RNA polymerase. The myxopyronin changes the structure of the switch-2 segment of the enzyme, inhibiting its function of reading and transmitting DNA code. This prevents RNA polymerase from delivering genetic information to the ribosomes, causing the bacteria to die.[91] In 2012, a team of the University of Leipzig modified a peptide found in honeybees. It is effective against 37 types of bacteria.[92] One major cause of antibiotic resistance is the increased pumping activity of microbial ABC transporters, which diminishes the effective drug concentration inside the microbial cell. ABC transporter inhibitors that can be used in combination with current antimicrobials are being tested in clinical trials and are available for therapeutic regimens.[]

Antibiotic resistance


Antibiotic resistance is an important tool for genetic engineering. By constructing a plasmid that contains an antibiotic resistance gene as well as the gene being engineered or expressed, a researcher can ensure that when bacteria replicate, only the copies that carry the plasmid survive. This ensures that the gene being manipulated passes along when the bacteria replicates. The most commonly used antibiotics in genetic engineering are generally "older" antibiotics that have largely fallen out of use in clinical practice. These include: ampicillin kanamycin tetracycline chloramphenicol

Industrially the use of antibiotic resistance is disfavored since maintaining bacterial cultures would require feeding them large quantities of antibiotics. Instead, the use of auxotrophic bacterial strains (and function-replacement plasmids) is preferred.

[2] D'Costa et al. 2011, pp.457461. [3] Donadio et al. 2010, pp.423430. [4] Caldwell & Lindberg 2011. [5] Nelson 2009, p.294. [6] Hawkey & Jones 2009, pp.i3-i10. [11] Healthcare-associated Infections [19] Richard William Nelson. Darwin, Then and Now: The Most Amazing Story in the History of Science, iUniverse, 2009, p. 294 [20] Wayne W. Umbreit, Advances in Applied Microbiology, vol. 11, Academic Press, 1970, p. 80 [21] M. R. Pollock. "Origin and Function of Penicillinase: a Problem in Biochemical Evolution",British Medical Journal, 14 Oct 1967, p. 76 [22] New Scientist, Jun 8, 1972, p. 546 [23] New Scientist, Feb 11, 1989, p. 34 [24] Pollock, p. 77 [25] Abigail A. Salyers, Dixie D. Whitt. Revenge of the microbes: how bacterial resistance is undermining the antibiotic miracle, ASM Press, 2005, p. 34 [42] Marc Bonten, MD; Eijkman-Winkler Institute for Medical Microbiology, Infectious Diseases, and Inflammation; Utrecht, the Netherland | http:/ / hicsigwiki. asid. net. au/ images/ 4/ 41/ Should_you_stop_an_antibiotic_course_early_if_you_feel_better_R. _Everts. pdf [48] Farmer, Paul E., Bruce Nizeye, Sara Stulac, and Salmaan Keshavjee. 2006. Structural Violence and Clinical Medicine. PLoS Medicine, 1686-1691. [51] http:/ / www. efsa. europa. eu/ EFSA/ Report/ biohaz_report_301_joint_mrsa_en,0. pdf [60] Martinez, J. L., & Olivares, J. (2012). Envrironmental Pollution By Antibiotic Resistance Genes. In P. L. Keen, & M. H. Montforts, Antimicrobial Resistance in the Environment (pp. 151- 171). Hoboken, N.J.: John Wiley & Sons. [61] Pruden, A., & Arabi, M. (2012). Quantifying Anthropogenic Impacts on Environmental Reservoirs of Antibiotic Resistance. In P. L. Keen, & M. H. Montforts, Antimicrobial Resistance in the Environment (pp. 173-202). Hoboken, N.J.: John Wiley & Sons. [89] Scientists discover possible antibiotics alternative (http:/ / www. abc. net. au/ news/ 2012-07-29/ australian-scientists-discover-antibiotic-alternative/ 4161926) - Australian Broadcasting Corporation Retrieved 29 July 2012. [90] https:/ / www. wp. dh. gov. uk/ publications/ files/ 2013/ 03/ CMO-Annual-Report-Volume-2-20111. pdf

Antibiotic resistance


Books Caldwell, Roy; Lindberg, David, eds. (2011). "Understanding Evolution" [Mutations are random] (http:// evolution.berkeley.edu/evolibrary/article/mutations_07). University of California Museum of Paleontology. Retrieved Aug 14, 2011. Nelson, Richard William (2009). Darwin, Then and Now: The Most Amazing Story in the History of Science (Self Published). iUniverse. p.294. Journals Arias, Cesar A.; Murray, BE (2009). "Antibiotic-Resistant Bugs in the 21st Century A Clinical Super-Challenge". New England Journal of Medicine 360 (5): 439443. doi: 10.1056/NEJMp0804651 (http:// dx.doi.org/10.1056/NEJMp0804651). PMID 19179312 (http://www.ncbi.nlm.nih.gov/pubmed/ 19179312). D'Costa, Vanessa; King, Christine; Kalan, Lindsay; Morar, Mariya; Sung, Wilson; Schwartz, Carsten; Froese, Duane; Zazula, Grant et al. (September 2011). "Antibiotic resistance is ancient". Nature 477 (7365): 457461. Bibcode: 2011Natur.477..457D (http://adsabs.harvard.edu/abs/2011Natur.477..457D). doi: 10.1038/nature10388 (http://dx.doi.org/10.1038/nature10388). PMID 21881561 (http://www.ncbi.nlm. nih.gov/pubmed/21881561). Donadio, Stefano; Maffioli, Sonia; Monciardini, Paolo; Sosio, Margherita; Jabes, Daniela (August 2010). "Antibiotic discovery in the twenty-first century: Current trends and future perspectives". The Journal of Antibiotics 63 (8): 423430. doi: 10.1038/ja.2010.62 (http://dx.doi.org/10.1038/ja.2010.62). PMID 20551985 (http://www.ncbi.nlm.nih.gov/pubmed/20551985). Goossens, H; Ferech, M; Vander Stichele, R; Elseviers, M; Esac Project, Group (2005). "Outpatient antibiotic use in Europe and association with resistance: a cross-national database study". Lancet. Group Esac Project 365 (9459): 57987. doi: 10.1016/S0140-6736(05)17907-0 (http://dx.doi.org/10.1016/S0140-6736(05)17907-0). PMID 15708101 (http://www.ncbi.nlm.nih.gov/pubmed/15708101). Hawkey, PM; Jones, AM (September 2009). "The changing epidemiology of resistance". The Journal of antimicrobial chemotherapy. 64 Suppl 1: i310. doi: 10.1093/jac/dkp256 (http://dx.doi.org/10.1093/jac/ dkp256). PMID 19675017 (http://www.ncbi.nlm.nih.gov/pubmed/19675017). Soulsby, EJ (2005). "Resistance to antimicrobials in humans and animals: Overusing antibiotics is not the only cause and reducing use is not the only solution" (http://www.bmj.com/cgi/content/full/331/7527/1219). BMJ 331 (7527): 121920. doi: 10.1136/bmj.331.7527.1219 (http://dx.doi.org/10.1136/bmj.331.7527. 1219). PMC 1289307 (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1289307). PMID 16308360 (http:// www.ncbi.nlm.nih.gov/pubmed/16308360). "Alternatives to Antibiotics Reduce Animal Disease" (http://www.csiro.au/solutions/ Alternatives-to-antibodies.html). Commonwealth Scientific and Industrial Research Organization. 9 Jan. 2006.

Antibiotic resistance


External links
Animation of Antibiotic Resistance (http://pharmaxchange.info/press/2011/02/ animation-of-antimicrobial-resistance/) CDC Article on Hospital Acquired MRSA (http://www.cdc.gov/ncidod/dhqp/ar_mrsa_spotlight_2006.html) CDC Article on Community Acquired MRSA (http://www.cdc.gov/ncidod/dhqp/ar_mrsa_ca.html) CDC Guideline "Management of Multidrug-Resistant Organisms in Healthcare Settings, 2006" (http://www. cdc.gov/ncidod/dhqp/pdf/ar/mdroGuideline2006.pdf) ReAct Action on Antibiotic Resistance (http://www.reactgroup.org/) Alliance for the Prudent Use of Antibiotics (http://www.apua.org/) Cox, L. A. (T.; Popken, D. A. (2006). "Quantifying Potential Human Health Impacts of Animal Antibiotic Use: Enrofloxacin and Macrolides in Chickens". Risk Analysis 26 (1): 135146. doi: 10.1111/j.1539-6924.2006.00723.x (http://dx.doi.org/10.1111/j.1539-6924.2006.00723.x). PMID 16492187 (http://www.ncbi.nlm.nih.gov/pubmed/16492187). Information about phage therapy a possible alternative to antibiotics in case of resistant infections (http:// www.bacteriophagetherapy.info/) Antibiotic-resistance genes as markers (http://www.gmo-safety.eu/basic-info/288. once-necessary-undesirable.html) Once necessary, now undesirable CBS Article on Phage Therapy and Antibiotic Resistance (http://web.archive.org/web/20071105214608/http:/ /cbs5.com/health/local_story_025195614.html) Hospitals: Breeding the Superbug (http://web.archive.org/web/20080610061943/http://knowledge.allianz. com/en/globalissues/safety_security/health_pandemics/hospital_infections_mrsa.html) Article on MRSA infections in hospitals, Allianz Knowledge, by Valdis Wish, May 2008. BURDEN of Resistance and Disease in European Nations - An EU-Project to estimate the financial burden of antibiotic resistance in European Hospitals (http://www.eu-burden.info/burden/pages/home.php) Extending the Cure: Policy Research to Extend Antibiotic Effectiveness (http://www.extendingthecure.org/) 2003 New Guidance for Industry on Antimicrobial Drugs for Food Animals Questions and Answers, U.S. FDA (http://web.archive.org/web/20071214142631/http://www.fda.gov/oc/antimicrobial/questions.html) SciDev.net Antibiotic Resistance spotlight (http://www.scidev.net/en/health/antibiotic-resistance/) The Science and Development Network is an online science and development network focused on news and information important to the developing world Do Bugs Need Drugs? (http://www.dobugsneeddrugs.org/) Combating Drug Resistance (http://www.pharmaceutical-int.com/article/combating-drug-resistance.html) Tackling drug resistance in bacteria and other pathogens. (http://www.technologyreview.com/news/513461/ nanoparticle-disguised-as-a-blood-cell-fights-bacterial-infection/?utm_campaign=newsletters& utm_source=newsletter-daily-all&utm_medium=email&utm_content=20130415) Nanoparticles could treat antibiotic resistant infections.

Article Sources and Contributors


Article Sources and Contributors

Antibiotic resistance Source: https://en.wikipedia.org/w/index.php?oldid=563572156 Contributors: -Paul-, 20I.170.20, 2602:306:3626:59F0:EDDB:4154:DBEF:CDDD, 6amiesh, AaronY, Abanima, Abcdefghayden, Achowat, Acroterion, Aetheling, AgainErick, Aldert, Alexius08, AlphaEta, Altenmann, Aman222, Aminullah, Amunroe13, Andrewcmcardle, Andy M. Wang, AnnaJune, Anniedg8, Anonymous56789, Antandrus, Anthonyhcole, Antifamilymang, Arcadian, Arch dude, Areejshahab, Arnavchaudhary, ArnoldReinhold, Art LaPella, Arthena, Ashton1983, Atlant, BD2412, Batmanand, Bchalfin, BenC7, Bender235, Bennetto, Bernfarr, Binksternet, Biosicherheit, Biraalo, Bobblewik, Brandmeister, Bubbachuck, BullRangifer, CMBJ, Cablehorn, Caleb615jet, CalendarWatcher, Calx, Can't sleep, clown will eat me, CatPath, CharlesClarkson, Chinacat, Chris the speller, ChrisGualtieri, Chuckmoran7, Ckocks71, Coldbringer, Conti, Conversion script, Craigsjones, Cuvtixo, DMacks, DVdm, Dangiankit, DanielDeibler, Davedgd, David Gerard, Davidruben, Dcirovic, Deli nk, Delldot, Delusion23, Dfgarcia, Dheenkumar, Discospinster, Djihed, Dmg46664, DocWatson42, DocendoDiscimus, DragonflySixtyseven, Drbreznjev, Dthomsen8, Duncan.france, DynamoDegsy, Dysmorodrepanis, Ed Poor, EdBever, Elias, Episeda, Erikaeb, Ettrig, Euyyn, EvilResident, Excirial, Favonian, Fconaway, Felisopus, FieldsTom, Forevercharlton, Fred Bauder, Fredil Yupigo, G. Vlcker, Gak, Gazpacho, GeoGreg, Gilliam, Glen, Glenalpine, Graft, GrahamColm, GregRM, Guitarist1897, Habasi, Hail.pudra, HamburgerRadio, Hamiltonian 80, Hankwang, Headbomb, HexaChord, Hooperbloob, Hu12, Imtiazdanny, Ingolfson, Invitatious, Iridescent, IronJohnSr, JFlin5, JWSchmidt, Jaganath, JameiLei, Jarble, Jaynil96, Jfdwolff, Jmb462, Jmh649, Jocce, John Mackenzie Burke, Johnathanbingley, Jonabbey, Jonkerz, Jonojrm, Jordi.planas, Jpalembas, Jsonitsac, Jtm71, Jubilee7, Julesd, JuniorMuruin, JustinSane, Jzlcdh, KVDP, Ke4roh, Keilana, Kerani, Kerrow, Kingdon, Kon-Tiki001, Krisoft79, Kyoko, Kyphe, Lab-oratory, Lancevortex, Lawrence1995, Leoniana, Lexor, Life of Riley, Light show, Lilxkasumi, Logan, Loren.wilton, LovesMacs, MC10, MER-C, MadCow257, Magicwombat, Magioladitis, Magnus Manske, Makeemlighter, Mandarax, MartinGugino, MatthewBChambers, Mav, Mbarbier, Mcstrother, Megdavisdvm, Mendaliv, Mentifisto, Miaers, Micromesistius, Mifter, Mike Rosoft, Mjacar92, Mkontkow, Monkeyjunky, Mr Stephen, MrADHD, Mthoodhood, Mtnclmbr4, Nanopharmacy, Narayanese, Nazgul02, Nhandler, NinaFay, Ninel, Nono64, Norm mit, Northfox, NotWith, NovaDog, Nsaa, OldakQuill, Olin, Olivier, Onthegogo, Orange Suede Sofa, Orangemarlin, Oxymoron83, PDH, Paralympiakos, Paul venter, Pdcook, Peak, Peregrine981, Peruvianllama, Petiatil, Pharaoh of the Wizards, Phedit, Philip Trueman, PhilipO, Pinkadelica, PrestonH, PseudoSudo, Pseudomonas, Purple Paint, Quantumor, Quotemstr, R Lowry, RDBrown, Radon210, Reach Out to the Truth, Reatlas, Reddi, Reedy, Rewster, Rich Farmbrough, Richard001, Rjwilmsi, Robert Merkel, Rod57, Rontp, RoyBoy, Rrburke, Rui Silva, Ryanrs, SDY, SGasper, SPUI, Sankynet, Sanya3, Scray, Seaphoto, SeoMac, Serrin, Seventypercent, Shalom Yechiel, SharkinthePool, Shisha-Tom, Shoeofdeath, Silvermask, Sj, Slakr, Sluzzelin, Smcauley, Sole Soul, Someone else, Sonjakranzfelder, Souad27, Sovietpride, Spaully, SpencerThiel, Splintercellguy, Spock014, SpuriousQ, Spyglasses, Ssilvers, StephanieM, Stevenfruitsmaak, Steveprutz, Stevertigo, StormWillLaugh, Sun Creator, SuperSonic, SvNH, TSChymist, TaintedMustard, Takometer, Tangotango, Telko631, Tennispro427, Terrell Larson, Tetsuo, The Anome, TheTito, Theskyking, Thue, Tide rolls, Tim1357, Timeloop, Tjarrett, Torst, Touchstone42, Tpbradbury, Transity, Triangular, Tsalman, Tuspm, TutterMouse, TwoOneTwo, Ultraexactzz, Uncle Milty, VIOLENTRULER, VanBuren, Vanished user 19794758563875, Vice regent, Vishnava, Visium, Vnahum, Vrenator, WLU, Wafulz, Wavelength, Wedian, WiKiMi3, Wikifitz, Wikipelli, Will Beback, Wingman4l7, Wouterstomp, Wuerzele, Wykis, Xabian40409, Xkonstantinex, Ylem, ZapThunderstrike, Zchahe7, Ziggaroth, Zorro CX, kebrke, 645 anonymous edits

Image Sources, Licenses and Contributors

File:Antibiotic sensitvity and resistance.JPG Source: https://en.wikipedia.org/w/index.php?title=File:Antibiotic_sensitvity_and_resistance.JPG License: Creative Commons Attribution-Sharealike 3.0 Contributors: User:GrahamColm File:Antibiotic resistance.svg Source: https://en.wikipedia.org/w/index.php?title=File:Antibiotic_resistance.svg License: Public Domain Contributors: Wykis File:mecA Resistance.svg Source: https://en.wikipedia.org/w/index.php?title=File:MecA_Resistance.svg License: Creative Commons Attribution 3.0 Contributors: Mcstrother

Creative Commons Attribution-Share Alike 3.0 Unported //creativecommons.org/licenses/by-sa/3.0/